Upstream Bio, Inc.
No enriched coverage for $UPB in the last 7 days.
No SEC Form 4 filings for $UPB in the last 30 days.
See all $UPB insider activity →Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0002022626 false 0002022626 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 09,
Upstream Bio announced it will present new Phase 2 VIBRANT trial data for verekitug, an antagonist to the TSLP receptor, at the ATS 2026 International Conference. The presentations will detail verekitug's clinical effect in chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid asthma and its impact on nasal and blood biomarkers. This data highlights the therapy's potential for severe respiratory disorders.
Upstream Bio (NASDAQ: UPB) has established an at-the-market (ATM) equity program, allowing it to offer and sell up to $150 million worth of its common stock through Leerink Partners LLC. This program provides the company with flexible access to capital, enabling sales of shares over time based on market conditions. Leerink Partners will receive a commission of up to 3.0% of the gross proceeds from these sales, and neither party is obligated to sell a minimum amount of shares.
Recent UPB coverage spans financial news and corporate actions.
Routine corporate governance update; no new operating/financial guidance or material transaction disclosed.
The upcoming presentation of Phase 2 VIBRANT trial data for verekitug by Upstream Bio is likely to positively influence investor sentiment and the stock price of UPB, especially among biotech investors focusing on respiratory disorder therapeutics.
Upstream Bio has announced a $150 million at-the-market stock program, providing the company with flexible capital access. The news indicates potential for stock dilution but also suggests confidence in future growth.
Upstream Bio's CEO participation in prominent healthcare conferences suggests positive industry visibility and potential for strategic partnerships.
Upstream Bio's participation in upcoming investor conferences indicates active engagement with investors and potential positive developments. The company's focus on inflammatory diseases, especially respiratory disorders, aligns with current healthcare trends.
alphai scores every news story that mentions UPB with an AI model for sentiment and relevance, and aggregates insider trades from Upstream Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Upstream Bio, Inc. (UPB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0002022626 false 0002022626 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 09,
2 min readUpstream Bio announced it will present new Phase 2 VIBRANT trial data for verekitug, an antagonist to the TSLP receptor, at the ATS 2026 International Conference. The presentations will detail verekitug's clinical effect in chronic rhinosinusitis with nasal polyps (CRSwNP) patients with comorbid asthma and its impact on nasal and blood biomarkers. This data highlights the therapy's potential for severe respiratory disorders.
4 min readUpstream Bio (NASDAQ: UPB) has established an at-the-market (ATM) equity program, allowing it to offer and sell up to $150 million worth of its common stock through Leerink Partners LLC. This program provides the company with flexible access to capital, enabling sales of shares over time based on market conditions. Leerink Partners will receive a commission of up to 3.0% of the gross proceeds from these sales, and neither party is obligated to sell a minimum amount of shares.
2 min readUpstream Bio's CEO, Rand Sutherland, MD, is scheduled to participate in fireside chats at two major healthcare conferences: the TDCowen Health Care Conference on March 4 and the LeerinkPartners Global Healthcare Conference on March 9. His appearances underscore the company's commitment to engaging in critical industry discussions.
3 min readWALTHAM, Mass., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc. ( NASDAQ:UPB ) , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream ...
2 min readWALTHAM, Mass., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Upstream Bio, Inc. ( Nasdaq: UPB ) , a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream ...
2 min read- Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric receptor complexes -
3 min read- Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites ...
2 min readVerekitug met all primary and key secondary endpoints, reducing nasal polyp and congestion scores over 24 weeks. No serious adverse events were reported, supporting a strong safety profile consistent with earlier studies. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day ...
3 min readUpstream Bio to Host Conference Call/Webcast to Report Top-Line Data from Phase 2 VIBRANT Trial of Verekitug in Patients with ...
3 min read
